Catalyst Dossier · compiled by CeliA 🧫
Sanofi (SNY)
Pharmaceutical Preparations · market cap $100.0B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-29 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Sanofi (SNY) is a French multinational pharmaceutical giant with a market cap of approximately $100B and ~83,000 employees, trading at ~$42.98 on Nasdaq. The company carries a broad late-stage pipeline spanning hemophilia, immunology, oncology, and infectious disease, with a recent PDUFA approval in June 2026 and multiple Phase 3 readouts expected through late 2026. Analyst consensus is Buy with a mean price target of ~$55.72, implying ~30% upside to current price.
The catalyst path
- 2026-09-29 (est.)Phase 2 · Amlitelimabimp 7/10
- 2026-10-14 (est.)Phase 3 · Itepekimab (SAR440340)imp 9/10
- 2026-10-15 (est.)Phase 2 · carmustine, etoposide, cytarabine, melphalanimp 7/10
- 2026-10-30Earningsimp 5/10
- 2026-11-05 (est.)Phase 3 · Fitusiranimp 9/10
- 2026-11-06 (est.)Phase 2 · Mometasone furoate nasal spray (MFNS)imp 7/10
- 2026-11-15 (est.)Phase 2 · Isatuximabimp 7/10
- 2026-11-30 (est.)Phase 3 · Rilzabrutinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SR147778 | Phase 2 | Obesity |
| XRP0038 (NV1FGF) | Phase 2 | Peripheral Arterial Disease |
| efanesoctocog alfa (BIVV001) | Phase 3 | Hemophilia A |
| Duvakitug | Phase 3 | Ulcerative Colitis |
| xaliproden (SR57746A) | Phase 3 | Alzheimer Disease |
| zolpidem-MR (SL800750) | Phase 3 | Sleep Initiation and Maintenance Disorders |
| A/H1N1 pandemic influenza vaccine (non- adjuvanted) | Phase 3 | Influenza |
| CYD dengue vaccine serotypes (1, 2, 3, 4). | Phase 2 | Dengue Virus |
| lactoserum | Phase 3 | Hygiene |
| DTaP-IPV-HB-PRP~T | Phase 3 | Diphtheria |
| Yellow fever vaccine (live) | Phase 3 | Yellow Fever Immunization |
| G-CSF Plus Plerixafor | Phase 2 | Hodgkin's Disease |
| SAR443122 | Phase 2 | Colitis Ulcerative |
| Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus | Phase 3 | Dengue |
| epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile | Phase 3 | Breast Neoplasms |
| Low Dose (LD) RSVt vaccine | Phase 3 | RSV Immunisation |
| Insulin glargine/lixisenatide fixed ratio combination | Phase 3 | Type 2 Diabetes Mellitus |
| RSV vaccine candidate | Phase 2 | Respiratory Syncytial Virus Infection |
| Fexofenadine | Phase 3 | Seasonal Allergic Rhinitis |
| rimonabant (SR141716) | Phase 3 | Obesity |
Price & technical context
3-month
+2.2%
6-month
-5.0%
12-month
-9.6%
52-wk range
$41.33–$52.34
vs 50-day MA
-3.1%
vs 200-day MA
-6.3%
Realized vol
24.1%
Max drawdown
-30.4%
Daily closes through 2026-09-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SNY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.